Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
JCO Oncology Practice · 2026-01 · 22 (1) · 19-35
DOI: 10.1200/op-25-00133 ↗Kurz gefasst
Leitlinie in der Zeitschrift JCO Oncology Practice, 2026-01. Verfasst von Kimberly Perez und 29 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms, Intestinal Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. METHODS ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice. RESULTS The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations. RECOMMENDATIONS Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA.
- Center for Cancer Research, National Cancer Institute, Bethesda, MD.
- American Society of Clinical Oncology, Alexandria, VA.
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Parel, Mumbai, India.
- University of Miami Health System, Miami, FL.
- Mayo Clinic School of Medicine, Rochester, MN.
ORCID-Profile: Kimberly Perez, Jaydira Del Rivero, Erin B Kennedy, Sandip Basu, Aman Chauhan, Heidi M Connolly, Arvind N Dasari, Callisia N Clarke, Julie Hallet, James R Howe, Erin Grady, Jana Ivanidze, Nitya P Raj, Namrata Vijayvergia, Pamela L Kunz, Josh Mailman, Junaid Arshad, Heloisa P Soares, Simron Singh, Michael C Soulen, Thorvardur R Halfdanarson, Jonathan R Strosberg
Zitieren
APA
Perez, K., Del Rivero, J., Kennedy, E. B., Basu, S., Chauhan, A., Connolly, H. M., Dasari, A. N., Gangi, A., Clarke, C. N., Hallet, J., Howe, J. R., Grady, E., Ivanidze, J., Mittra, E. S., White, S. B., Raj, N. P., Vijayvergia, N., Lewis, M. A., Chan, J. A., …, & Bergsland, E. K. (2026). Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncology Practice, 22(1), 19-35. https://doi.org/10.1200/op-25-00133
Vancouver
Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, et al. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncology Practice. 2026;22(1):19-35. doi:10.1200/op-25-00133
BibTeX
@article{Perez2026,
author = {Perez, Kimberly and Del Rivero, Jaydira and Kennedy, Erin B and Basu, Sandip and Chauhan, Aman and Connolly, Heidi M and Dasari, Arvind N and Gangi, Alexandra and Clarke, Callisia N and Hallet, Julie and Howe, James R and Grady, Erin and Ivanidze, Jana and Mittra, Erik S and White, Sarah B and Raj, Nitya P and Vijayvergia, Namrata and Lewis, Mark A and Chan, Jennifer A and Kunz, Pamela L and Mailman, Josh and Arshad, Junaid and Soares, Heloisa P and Singh, Simron and Chandrasekharan, Chandrika and Soulen, Michael C and Janson, Eva Tiensuu and Halfdanarson, Thorvardur R and Strosberg, Jonathan R and Bergsland, Emily K},
title = {Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline},
journal = {JCO Oncology Practice},
year = {2026},
volume = {22},
number = {1},
pages = {19--35},
doi = {10.1200/op-25-00133}
}
EUVIMED